| 000 | 01781 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513123406.0 | ||
| 264 | 0 | _c19971014 | |
| 008 | 199710s 0 0 eng d | ||
| 022 | _a0885-3185 | ||
| 024 | 7 |
_a10.1002/mds.870120404 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLyytinen, J | |
| 245 | 0 | 0 |
_aSimultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease. _h[electronic resource] |
| 260 |
_bMovement disorders : official journal of the Movement Disorder Society _cJul 1997 |
||
| 300 |
_a497-505 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xpharmacology |
| 650 | 0 | 4 | _aBenserazide |
| 650 | 0 | 4 | _aCatechol O-Methyltransferase Inhibitors |
| 650 | 0 | 4 |
_aCatechols _xpharmacology |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xpharmacokinetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMonoamine Oxidase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aMotor Activity _xdrug effects |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aParkinson Disease _xblood |
| 650 | 0 | 4 |
_aSelegiline _xpharmacology |
| 700 | 1 | _aKaakkola, S | |
| 700 | 1 | _aAhtila, S | |
| 700 | 1 | _aTuomainen, P | |
| 700 | 1 | _aTeräväinen, H | |
| 773 | 0 |
_tMovement disorders : official journal of the Movement Disorder Society _gvol. 12 _gno. 4 _gp. 497-505 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/mds.870120404 _zAvailable from publisher's website |
| 999 |
_c9230785 _d9230785 |
||